{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"partial response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"minimal response (MR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"progression of disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"The maximum response for all patients that were treated on study. Maximum response was assessed using the International myeloma working group (IMWG) guidelines for response. http://imwg.myeloma.org/international-myeloma-working-group-imwg-uniform-response-criteria-for-multiple-myeloma/","groups":[{"description":"All patients were treated with the DexTR (dexamethasone / thalidomide, lenalidomide (Revlimid®)), which consisted of lenalidomide 25mg/day during days 1-21, dexamethasone 40mg/day on days 1-4, 9-12, and 17-20, and thalidomide 50mg/day for the first 7 days, followed by 100mg/day for all subsequent days, for a total of 4 cycles of 28 days each.\n\ndexamethasone: Cycles 1-4\n\n• Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.\n\nAfter completing 4 cycles:\n\n* Patients who demonstrate disease progression at any time will be taken off study.\n* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \\> 2 cycles will be transitioned to maintenance therapy.\n* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \\>2 cycles or CR in the absence of unt","id":"OG000","title":"DexTR (All Patients)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"The best response for all patients at any point were assessed for patients that were treated on study, from start of treatment up to 20 weeks","title":"Effect of Drug Combination on Multiple Myeloma","type":"PRIMARY","unitOfMeasure":"participants"}